Clinical Trial Update: GR1803 Injection in Patients With RRMM [Phase 2]

View source ↗

Summary

GR1803 is being studied in relapsed/refractory multiple myeloma in a Phase 2 trial, and recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• GR1803

Snippet

Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Conditions: Multiple Myleoma | Phase 2 | Status: RECRUITING